A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe

Completed

• Conditions: Ophthalmology, Macular Degeneration

• Registration Number: NCT04067583
• Lead Sponsor: Bayer

Brief Summary

With this follow up physician survey researcher want to collect the same data from all participants of the study using a highly structured questionnaire. The questionnaire will gather information related to physician characteristics and experience with Aflibercept, as well as assess physicians' knowledge and understanding of storage and preparation, proper injection technique, and the risks associated with Aflibercept injection into the eye (intravitreal injection). Analysis will be done using descriptive statistics.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-08-22
• Study First Submitted QC: 2019-08-22
• Study First Posted: 2019-08-26
• Study Start: 2019-10-08
• Primary Completion: 2020-04-15
• Study Completion: 2020-04-23
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-06
• Last Update Posted: 2021-04-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 454

Inclusion Criteria

• Has signed informed consent
• Is a licensed and practicing ophthalmologist
• Has prescribed and/or administered aflibercept to at least one patient in the past 6 months

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of physicians responding correctly to each individual knowledge question	Up to 1 year

Trial Locations

Locations (1)

Many locations; 🇩🇪 Multiple Locations, Germany

Many locations

🇩🇪Multiple Locations, Germany